Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin Post published:December 14, 2021 Post category:Press Release
MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer Post published:December 14, 2021 Post category:Press Release
MAPS and Wesana Health Resume Negotiations Post published:December 14, 2021 Post category:Press Release
Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality Post published:December 14, 2021 Post category:Press Release
MindMed Appoints Robert Barrow as Chief Executive Officer and Director Post published:December 14, 2021 Post category:Press Release
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia Post published:December 14, 2021 Post category:Press Release
Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021 Post published:December 14, 2021 Post category:Press Release
Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R) Market in the United States Post published:December 13, 2021 Post category:Press Release
PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian Glaucoma Society to Their Scientific Advisory Board to Enhance Ongoing DMT Studies to Treat Glaucoma Post published:December 13, 2021 Post category:Press Release
HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes Post published:December 13, 2021 Post category:Press Release